Amerimmune focuses on advancing immunology solutions through a combination of clinical diagnostics, research, and development. One of their key technologies is the Basophil Activation Test (BAT), which assesses the activation of basophils—white blood cells that play a crucial role in allergic responses. This test helps in understanding and diagnosing allergic conditions by measuring the release of substances from basophils in response to allergens. Additionally, Amerimmune is involved in innovative research related to COVID-19, particularly examining the role of caspases in immune responses and their potential implications for severe outcomes in COVID-19 patients.

The company also emphasizes the development of diagnostic tools, such as a virtual peanut allergy test, which aims to streamline the testing process by allowing patients to provide samples at partner locations like Quest Diagnostics. Amerimmune's team comprises experts with extensive backgrounds in immunology and molecular biology, who are dedicated to creating novel laboratory-developed tests (LDTs) and improving healthcare outcomes for patients with primary immunodeficiencies and allergies. Their commitment to evidence-based medicine drives their approach to finding effective solutions for complex immune disorders.

United States

The mission of Amerimmune is to innovate in diagnoses and therapies of immune and allergic disorders.

Amerimmune

Company Details